Generic-drug-maker Hospira has sold more than 5 million doses of biosimilar drugs to European and Australian patients, and it plans to open access to biosimilars in the U.S., said Thomas Moore, the company's president for global pharmaceuticals. The FDA has yet to finalize an approval pathway for biosimilar drugs, and some states have considered laws that would restrict pharmacists' ability to substitute biosimilars for their branded counterparts.

Full Story:
Drug Store News

Related Summaries